Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Academic Article DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Academic Article High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Academic Article Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Academic Article Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Academic Article Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Academic Article Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Academic Article Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Academic Article Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
Academic Article Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Concept Dexamethasone
Academic Article Total Therapy 3 (2003-33) in Gene Expression Profiling-Defined Low-Risk Multiple Myeloma Confirmed in Subsequent Trial 2006-66 with Bortezemib, Lenalidomide and Dexamethasone (VRD) Maintenance
Academic Article Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance
Grant A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomiib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Academic Article Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Academic Article Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial.
Academic Article Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.

Search Criteria
  • Dexamethasone